Evidence demonstrating that elevated expression of dUTPase protects breast cancer cells from the expansion of the intracellular uracil pool, translating to reduced growth inhibition following treatment with 5-FU is provided. The implementation of in silico drug development techniques to identify and develop small molecule inhibitors of dUTPase are reported. As 5-FU and the oral 5-FU pro-drug capecitabine remain central agents in the treatment of a variety of malignancies, the clinical utility of a small molecule inhibitor to dUTPase represents a viable strategy to improve the clinical efficacy of these mainstay chemotherapeutic agents.
申请公布号
WO2010025308(A3)
申请公布日期
2010.04.22
申请号
WO2009US55264
申请日期
2009.08.27
申请人
UNIVERSTIY OF SOUTHERN CALIFORNIA;LANDNER, ROBERT, D.;NEMATI, NOURI